Melanoma, while representing less than 5% of skin cancer cases, accounts for the majority of skin cancer deaths. The discovery of BRAF mutations and subsequent targeted therapy with BRAF/MEK inhibitors, combined with the transformative success of immune checkpoint inhibitor combination therapy, has dramatically altered the outlook for advanced disease. Adjuvant immunotherapy and targeted therapy are now standard in high-risk resected disease.
Small Molecules VS CAR-T In CLL
By the time CAR-T arrived in CLL, the disease had already been transformed by BTK inhibitors and venetoclax. TRANSCEND CLL 004 showed 18% CR in BTKi/venetoclax-refractory disease. Sarah Mitchell and James Carter explore why CLL is harder for CAR-T, where it...
Moving CAR-T To Earlier Myeloma Lines
Ciltacabtagene autoleucel achieved a 97% overall response rate and 67% complete response in triple-class refractory multiple myeloma - numbers not thought achievable a decade ago. CARTITUDE-4 has now moved it to the second line. Sarah Mitchell and James Car...